{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "29615704", "DateCompleted": {"Year": "2019", "Month": "10", "Day": "02"}, "DateRevised": {"Year": "2021", "Month": "08", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "04", "Day": "03"}], "Language": ["eng"], "ELocationID": ["5524", "10.1038/s41598-018-23768-7"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "8", "Issue": "1", "PubDate": {"Year": "2018", "Month": "Apr", "Day": "03"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Virtual screening, Docking, ADMET and System Pharmacology studies on Garcinia caged Xanthone derivatives for Anticancer activity.", "Pagination": {"StartPage": "5524", "MedlinePgn": "5524"}, "Abstract": {"AbstractText": ["Caged xanthones are bioactive compounds mainly derived from the Garcinia genus. In this study, a structure-activity relationship (SAR) of caged xanthones and their derivatives for anticancer activity against different cancer cell lines such as A549, HepG2 and U251 were developed through quantitative (Q)-SAR modeling approach. The regression coefficient (r<sup>2</sup>), internal cross-validation regression coefficient (q<sup>2</sup>) and external cross-validation regression coefficient (pred_r<sup>2</sup>) of derived QSAR models were 0.87, 0.81 and 0.82, for A549, whereas, 0.87, 0.84 and 0.90, for HepG2, and 0.86, 0.83 and 0.83, for U251 respectively. These models were used to design and screened the potential caged xanthone derivatives. Further, the compounds were filtered through the rule of five, ADMET-risk and synthetic accessibility. Filtered compounds were then docked to identify the possible target binding pocket, to obtain a set of aligned ligand poses and to prioritize the predicted active compounds. The scrutinized compounds, as well as their metabolites, were evaluated for different pharmacokinetics parameters such as absorption, distribution, metabolism, excretion, and toxicity. Finally, the top hit compound 1G was analyzed by system pharmacology approaches such as gene ontology, metabolic networks, process networks, drug target network, signaling pathway maps as well as identification of off-target proteins that may cause adverse reactions."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Metabolic & Structural Biology Department, CSIR-Central Institute of Medicinal & Aromatic Plants, P.O.-CIMAP, Lucknow, 226015, Uttar Pradesh, India."}, {"Identifier": [], "Affiliation": "Academy of Scientific & Innovative Research (AcSIR), CSIR-CIMAP Campus, Lucknow, 226015, Uttar Pradesh, India."}], "LastName": "Alam", "ForeName": "Sarfaraz", "Initials": "S"}, {"Identifier": ["0000-0002-7246-8687"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Metabolic & Structural Biology Department, CSIR-Central Institute of Medicinal & Aromatic Plants, P.O.-CIMAP, Lucknow, 226015, Uttar Pradesh, India. f.khan@cimap.res.in."}, {"Identifier": [], "Affiliation": "Academy of Scientific & Innovative Research (AcSIR), CSIR-CIMAP Campus, Lucknow, 226015, Uttar Pradesh, India. f.khan@cimap.res.in."}, {"Identifier": [], "Affiliation": "Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego (UCSD), 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA. f.khan@cimap.res.in."}], "LastName": "Khan", "ForeName": "Feroz", "Initials": "F"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "ESR1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Estrogen Receptor alpha"}, {"RegistryNumber": "0", "NameOfSubstance": "Xanthones"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Absorption, Physicochemical"}, {"QualifierName": ["adverse effects", "chemistry", "metabolism", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Evaluation, Preclinical"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Estrogen Receptor alpha"}, {"QualifierName": ["chemistry"], "DescriptorName": "Garcinia"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Protein Conformation"}, {"QualifierName": [], "DescriptorName": "Quantitative Structure-Activity Relationship"}, {"QualifierName": [], "DescriptorName": "Safety"}, {"QualifierName": [], "DescriptorName": "User-Computer Interface"}, {"QualifierName": ["adverse effects", "chemistry", "metabolism", "pharmacology"], "DescriptorName": "Xanthones"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016;66:7\u201330.", "ArticleIdList": ["26742998"]}, {"Citation": "Stewart, B. World Cancer Report 2014. (IARC Press, 2014)."}, {"Citation": "Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010\u20132020) by cancer groups. Asian Pac J Cancer Prev. 2010;11:1045\u20139.", "ArticleIdList": ["21133622"]}, {"Citation": "Kaur, R., Kapoor, K. & Kaur, H. Plants as a source of anticancer agents. Journal of Natural Product and Plant Resources 119\u2013124 (2011)."}, {"Citation": "H Ravi\u00f1a, E. The evolution of drug discovery: from traditional medicines to modern drugs. (Wiley-VCH, 2011)."}, {"Citation": "Auterhoff H, Frauendorf H, Senklas WL, Schwandt C. Der Hauptbestandteil des Guttiharzes. 1. Mitt.: Chemie des Gummigutts. Archiv der Pharmazie. 1962;295:833\u2013846. doi: 10.1002/ardp.19622951106.", "ArticleIdList": ["10.1002/ardp.19622951106", "13965598"]}, {"Citation": "Chantarasriwong O, Batova A, Chavasiri W, Theodorakis EA. Chemistry and Biology of the CagedGarciniaXanthones. Chemistry - A European Journal. 2010;16:9944\u20139962. doi: 10.1002/chem.201000741.", "ArticleIdList": ["10.1002/chem.201000741", "PMC3144150", "20648491"]}, {"Citation": "Han Q-B, Xu H-X. Caged Garcinia Xanthones: Development Since 1937. Current Medicinal Chemistry. 2009;16:3775\u20133796. doi: 10.2174/092986709789104993.", "ArticleIdList": ["10.2174/092986709789104993", "19747141"]}, {"Citation": "Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nature Reviews Drug Discovery. 2005;4:649\u2013663. doi: 10.1038/nrd1799.", "ArticleIdList": ["10.1038/nrd1799", "16056391"]}, {"Citation": "Jorgensen WL. The Many Roles of Computation in Drug Discovery. Science. 2004;303:1813\u20131818. doi: 10.1126/science.1096361.", "ArticleIdList": ["10.1126/science.1096361", "15031495"]}, {"Citation": "Kalyaanamoorthy S, Chen Y-PP. Structure-based drug design to augment hit discovery. Drug Discovery Today. 2011;16:831\u2013839. doi: 10.1016/j.drudis.2011.07.006.", "ArticleIdList": ["10.1016/j.drudis.2011.07.006", "21810482"]}, {"Citation": "Cucurull-Sanchez L, Spink K, Moschos S. Relevance of systems pharmacology in drug discovery. Drug Discovery Today. 2012;17:665\u2013670. doi: 10.1016/j.drudis.2012.01.015.", "ArticleIdList": ["10.1016/j.drudis.2012.01.015", "22405899"]}, {"Citation": "Nantasenamat C, Isarankura-Na-Ayudhya C, Prachayasittikul V. Advances in computational methods to predict the biological activity of compounds. Expert Opinion on Drug Discovery. 2010;5:633\u2013654. doi: 10.1517/17460441.2010.492827.", "ArticleIdList": ["10.1517/17460441.2010.492827", "22823204"]}, {"Citation": "Manglik A, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016;537:185\u2013190. doi: 10.1038/nature19112.", "ArticleIdList": ["10.1038/nature19112", "PMC5161585", "27533032"]}, {"Citation": "Validation of (Q)SAR Models. Validation of (Q)SAR Models - OECDAvailable at: http://www.oecd.org/chemicalsafety/risk-assessment/validationofqsarmodels.htm. (Accessed: 8th November 2017)."}, {"Citation": "Boda K, Seidel T, Gasteiger J. Structure and reaction based evaluation of synthetic accessibility. Journal of Computer-Aided Molecular Design. 2007;21:311\u2013325. doi: 10.1007/s10822-006-9099-2.", "ArticleIdList": ["10.1007/s10822-006-9099-2", "17294248"]}, {"Citation": "Ekins S, et al. Computational prediction of human drug metabolism. Expert Opinion on Drug Metabolism & Toxicology. 2005;1:303\u2013324. doi: 10.1517/17425255.1.2.303.", "ArticleIdList": ["10.1517/17425255.1.2.303", "16922645"]}, {"Citation": "Lohr J, Willsky G, Acara M. Renal Drug Metabolism. Pharmacological Reviews. 1998;50:107\u2013142.", "ArticleIdList": ["9549760"]}, {"Citation": "Handschin C. Induction of Drug Metabolism: The Role of Nuclear Receptors. Pharmacological Reviews. 2003;55:649\u2013673. doi: 10.1124/pr.55.4.2.", "ArticleIdList": ["10.1124/pr.55.4.2", "14657421"]}, {"Citation": "Staels, B. & Fonseca, V. A. Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration. Diabetes Care32 (2009).", "ArticleIdList": ["PMC2811459", "19875558"]}, {"Citation": "Gachon FCACA, Firsov D. The role of circadian timing system on drug metabolism and detoxification. Expert Opinion on Drug Metabolism & Toxicology. 2010;7:147\u2013158. doi: 10.1517/17425255.2011.544251.", "ArticleIdList": ["10.1517/17425255.2011.544251", "21192771"]}, {"Citation": "Lee, S., Lee, K. H., Song, M. & Lee, D. Building the process-drug\u2013side effect network to discover the relationship between biological Processes and side effects. BMC Bioinformatics12 (2011).", "ArticleIdList": ["PMC3073182", "21489221"]}, {"Citation": "Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug Target Identification Using Side-Effect Similarity. Science. 2008;321:263\u2013266. doi: 10.1126/science.1158140.", "ArticleIdList": ["10.1126/science.1158140", "18621671"]}, {"Citation": "Alam, S. & Khan, F. QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase Ii\u03b1. Drug Design, Development and Therapy 183 (2014).", "ArticleIdList": ["PMC3916431", "24516330"]}, {"Citation": "Gobbi A, Lee M-L. DISE:\u2009 Directed Sphere Exclusion. Journal of Chemical Information and Computer Sciences. 2003;43:317\u2013323. doi: 10.1021/ci025554v.", "ArticleIdList": ["10.1021/ci025554v", "12546567"]}, {"Citation": "Alam, S. & Khan, F. QSAR, docking, ADMET, and system pharmacology studies on tormentic acid derivatives for anticancer activity. Journal of Biomolecular Structure and Dynamics 1\u201318 (2017).", "ArticleIdList": ["28705120"]}, {"Citation": "Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews. 1997;23:3\u201325. doi: 10.1016/S0169-409X(96)00423-1.", "ArticleIdList": ["10.1016/S0169-409X(96)00423-1", "11259830"]}, {"Citation": "Singh A, et al. Anticancer activity of gallic acid template-based benzylidene indanone derivative as microtubule destabilizer. Chemical Biology & Drug Design. 2016;88:625\u2013634. doi: 10.1111/cbdd.12805.", "ArticleIdList": ["10.1111/cbdd.12805", "27495835"]}, {"Citation": "Berman HM. The Protein Data Bank. Nucleic Acids Research. 2000;28:235\u2013242. doi: 10.1093/nar/28.1.235.", "ArticleIdList": ["10.1093/nar/28.1.235", "PMC102472", "10592235"]}, {"Citation": "Kalani K, Chaturvedi V, Alam S, Khan F, Srivastava S. Anti-Tubercular Agents from Glycyrrhiza glabra. Current Topics in Medicinal Chemistry. 2015;15:1043\u20131049. doi: 10.2174/1568026615666150317223323.", "ArticleIdList": ["10.2174/1568026615666150317223323", "25786503"]}, {"Citation": "Singh S, et al. Synthesis of 3,5-dihydroxy-7,8-dimethoxy-2-(4-methoxyphenyl)benzopyran-4-one derivatives as anticancer agents. Bioorganic & Medicinal Chemistry Letters. 2016;26:5322\u20135327. doi: 10.1016/j.bmcl.2016.09.036.", "ArticleIdList": ["10.1016/j.bmcl.2016.09.036", "27671497"]}, {"Citation": "Ponnam D, et al. Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation. European Journal of Medicinal Chemistry. 2014;87:735\u2013744. doi: 10.1016/j.ejmech.2014.10.013.", "ArticleIdList": ["10.1016/j.ejmech.2014.10.013", "25305717"]}, {"Citation": "Kumar BS, et al. Recent Advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug. Steroids. 2016;110:9\u201334. doi: 10.1016/j.steroids.2016.03.017.", "ArticleIdList": ["10.1016/j.steroids.2016.03.017", "27020471"]}, {"Citation": "Singh A, et al. Diethyl-4,4\u2032-dihydroxy-8,3\u2032-neolign-7,7\u2032-dien-9,9\u2032-dionate exhibits antihypertensive activity in rats through increase in intracellular cGMP level and blockade of calcium channels. European Journal of Pharmacology. 2017;799:84\u201393. doi: 10.1016/j.ejphar.2017.01.044.", "ArticleIdList": ["10.1016/j.ejphar.2017.01.044", "28159537"]}, {"Citation": "Alam, S. & Khan, F. 3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7. Scientific Reports7 (2017).", "ArticleIdList": ["PMC5519539", "28729623"]}]}], "History": [{"Year": "2017", "Month": "11", "Day": "16"}, {"Year": "2018", "Month": "3", "Day": "20"}, {"Year": "2018", "Month": "4", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "4", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "10", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "4", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["29615704", "PMC5883056", "10.1038/s41598-018-23768-7", "10.1038/s41598-018-23768-7"]}}]}